GO:0004061 arylformamidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004061 arylformamidase activity catalyzes the hydrolysis of N-formyl-L-kynurenine to formate and L-kynurenine, a critical step in the kynurenine pathway.
• The enzyme is a serine hydrolase with a catalytic triad (Ser-His-Asp/Glu) and is inhibited by organophosphorus toxicants.
• Arylformamidase is conserved from bacteria to mammals, with structural and kinetic studies in Drosophila and rat brain confirming its role.
• Genetic inactivation of the arylformamidase gene in mice alters kynurenine pathway metabolites and produces phenotypic changes, linking the enzyme to neuroactive metabolite production.
• Dysregulation of kynurenine pathway enzymes, including arylformamidase, is implicated in cancer progression, such as bladder cancer.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of arylformamidase function in health and disease.
Description
Arylformamidase activity (GO:0004061) is a molecular function defined as the catalysis of the reaction: N-formyl-L-kynurenine + H2O = formate + L-kynurenine. This enzymatic step is essential in the kynurenine pathway, which converts tryptophan into several neuroactive and immunomodulatory metabolites. The enzyme is also known as kynurenine formamidase and belongs to the serine hydrolase family. Because the kynurenine pathway is involved in neurological disorders, immune regulation, and cancer, understanding arylformamidase activity is of broad biomedical interest. Researchers study this enzyme to map metabolic fluxes, identify therapeutic targets, and interpret genetic variants that affect pathway output. The enzyme has been characterized biochemically and structurally in multiple species, revealing a conserved catalytic mechanism. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of arylformamidase activity, its genes, regulation, disease links, and experimental methods.
arylformamidase activity At A Glance
| GO ID | GO:0004061 |
|---|---|
| GO term | arylformamidase activity |
| Ontology | molecular_function |
| Synonym | kynurenine formamidase activity; formylkynureninase activity; formamidase I; formamidase II; formylase activity; aryl-formylamine amidohydrolase activity; formylkynurenine formamidase activity |
| Major function | Catalyzes the hydrolysis of N-formyl-L-kynurenine to formate and L-kynurenine |
| Catalytic residues | Serine hydrolase catalytic triad (Ser-His-Asp/Glu) |
| Inhibitors | Organophosphorus toxicants |
| Species distribution | Conserved from bacteria to mammals; studied in Drosophila, rat, mouse, and human |
What Is GO:0004061?
Arylformamidase activity (GO:0004061) is the catalytic function that hydrolyzes N-formyl-L-kynurenine into formate and L-kynurenine. This reaction removes a formyl group from the kynurenine pathway intermediate, enabling subsequent metabolic steps. The activity is synonymous with kynurenine formamidase, formylkynureninase, and formamidase I/II, reflecting its historical names.
Why Is arylformamidase activity Important in Cell Biology?
Arylformamidase activity is a key control point in the kynurenine pathway, which produces neuroactive metabolites such as kynurenic acid and quinolinic acid. By converting N-formyl-L-kynurenine to L-kynurenine, the enzyme directly influences the availability of substrates for downstream branches that affect neuronal excitability, immune responses, and cancer progression. Genetic inactivation of the enzyme in mice alters metabolite levels and phenotype, underscoring its physiological importance. Moreover, its serine hydrolase mechanism makes it a potential target for toxicants and drugs. Thus, arylformamidase activity is relevant to neurobiology, immunology, oncology, and toxicology.
• Controls a rate-limiting step in the kynurenine pathway, affecting neuroactive metabolite production.
• Genetic inactivation in mice changes kynurenine pathway metabolites and phenotype.
• Serine hydrolase mechanism is targeted by organophosphorus toxicants.
• Altered expression of kynurenine pathway enzymes, including arylformamidase, is associated with bladder cancer progression.
• Provides a model for studying catalytic differences between zinc- and manganese-dependent enzymes.
• Conserved structure and catalytic triad enable comparative studies across species.
• Potential biomarker or therapeutic target in diseases involving kynurenine dysregulation.
• Enables metabolic flux analysis when combined with CRISPR models.
• Supports drug discovery efforts targeting serine hydrolases.
• Facilitates understanding of tryptophan metabolism in brain and immune cells.
Molecular Mechanism of arylformamidase activity
Substrate Binding and Catalytic Triad
In simple terms: The enzyme uses a trio of amino acids to break down its substrate.
Arylformamidase is a serine hydrolase with a catalytic triad composed of serine, histidine, and aspartate/glutamate residues. The substrate N-formyl-L-kynurenine binds in the active site, positioning the formyl group for nucleophilic attack by the serine hydroxyl. Mutagenesis and modeling studies have confirmed the identity of these catalytic residues.
Hydrolysis Reaction
In simple terms: Water is used to split the substrate into two products.
The catalytic mechanism involves hydrolysis of the amide bond between the formyl group and the kynurenine moiety, releasing formate and L-kynurenine. This reaction is essential for the kynurenine pathway, as it generates L-kynurenine for downstream enzymes.
Cofactors and Metal Dependence
In simple terms: The enzyme does not require a metal cofactor for activity.
Unlike some hydrolases, arylformamidase activity is metal-independent; it relies on the catalytic triad for catalysis. However, comparative studies with bacterial isatin hydrolase have highlighted fundamental catalytic differences between zinc- and manganese-dependent enzymes, providing evolutionary context.
Inhibition by Organophosphorus Compounds
In simple terms: Certain toxicants can block the enzyme by modifying its active site serine.
Organophosphorus toxicants inhibit serine hydrolases, including arylformamidase, by phosphorylating the catalytic serine. This inhibition can disrupt kynurenine pathway flux and has implications for toxicology and drug design.
Structural Conservation
In simple terms: The enzyme's shape and active site are similar across species.
Crystal structures and homology models from Drosophila melanogaster and rat reveal a conserved alpha/beta hydrolase fold with the catalytic triad in a canonical arrangement. This conservation supports the use of model organisms to study human arylformamidase function.
Key Genes Involved in GO:0004061 arylformamidase activity
The following genes and proteins are directly associated with arylformamidase activity or its regulation in the kynurenine pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AFMID (human) | Encodes arylformamidase, catalyzing N-formyl-L-kynurenine hydrolysis | Target for knockout and point mutation studies in human cells |
| Afmid (mouse) | Ortholog of human AFMID; enzyme in kynurenine pathway | Gene inactivation alters metabolites and phenotype |
| Afmid (rat) | Formamidase activity in brain | Early biochemical characterization |
| KMO | Kynurenine 3-monooxygenase, downstream of arylformamidase | Competes for L-kynurenine; relevant to neurodegeneration |
| KYNU | Kynureninase, downstream enzyme | Metabolizes L-kynurenine; linked to immune regulation |
| TDO2 | Tryptophan 2,3-dioxygenase, upstream of arylformamidase | Controls tryptophan flux into kynurenine pathway |
| IDO1 | Indoleamine 2,3-dioxygenase 1, upstream enzyme | Immune checkpoint; affects kynurenine levels |
| IDO2 | Indoleamine 2,3-dioxygenase 2, upstream enzyme | Paralog of IDO1; less characterized |
| QPRT | Quinolinate phosphoribosyltransferase, downstream | Determines NAD+ synthesis from kynurenine pathway |
| HAAO | 3-hydroxyanthranilate 3,4-dioxygenase, downstream | Produces quinolinic acid, a neurotoxin |
| ACMSD | Aminocarboxymuconate semialdehyde decarboxylase | Regulates flux toward NAD+ vs. neurotoxin |
| SERPINA3 | Serine protease inhibitor, not directly related | May interact with serine hydrolases; context-dependent |
| PNPLA6 | Neuropathy target esterase, serine hydrolase | Model for organophosphorus inhibition |
| BCHE | Butyrylcholinesterase, serine hydrolase | Organophosphorus target; comparison to arylformamidase |
| ACHE | Acetylcholinesterase, serine hydrolase | Organophosphorus target; toxicological relevance |
| AFMID (Drosophila) | Ortholog in D. melanogaster | Crystal structure and kinetics |
| AFMID (bacterial) | Isatin hydrolase homolog | Catalytic differences between Zn/Mn enzymes |
| AFMID (zebrafish) | Ortholog in Danio rerio | Potential developmental model |
How Is arylformamidase activity Regulated?
Arylformamidase activity is regulated at multiple levels. Transcriptional regulation of the AFMID gene responds to immune signals and metabolic demand, as seen in cancer where kynurenine pathway enzymes show stage-dependent expression changes. Enzyme activity can be inhibited post-translationally by organophosphorus compounds that modify the catalytic serine. Additionally, substrate availability from upstream enzymes (TDO2, IDO1/2) influences flux through arylformamidase. In mice, genetic inactivation of Afmid alters metabolite levels, indicating that gene dosage and enzyme abundance are key determinants of pathway output.
arylformamidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AFMID | Bladder cancer progression | Knockout and overexpression in bladder cancer cell lines |
| AFMID | Neurological disorders | Brain-specific knockout in mice |
| AFMID | Organophosphate toxicity | Point mutation of catalytic serine in cell models |
| KMO | Huntington's disease | Knock-in of mutant KMO in neurons |
| IDO1 | Cancer immunotherapy | Knockout in tumor cells and immune co-culture |
Cancer Progression
Dysregulation of the kynurenine pathway is increasingly recognized in cancer. Stage-dependent changes in kynurenine pathway enzyme expression, including arylformamidase, suggest immune-related involvement in bladder cancer progression. The enzyme's product, L-kynurenine, can promote immune tolerance and tumor growth, making arylformamidase a potential target for cancer therapy.
Neurological and Psychiatric Disorders
The kynurenine pathway produces neuroactive metabolites such as kynurenic acid and quinolinic acid. Arylformamidase activity controls the availability of L-kynurenine for these branches, and its dysfunction may contribute to neuroinflammation and excitotoxicity. Early studies identified formamidase activity in rat brain, supporting a role in cerebral tryptophan metabolism.
Toxicology and Enzyme Inhibition
Organophosphorus toxicants inhibit serine hydrolases, including arylformamidase, by phosphorylating the active site serine. This inhibition can disrupt kynurenine pathway homeostasis and may contribute to neurotoxicity. Understanding the structural basis of inhibition aids in developing protective or therapeutic strategies.
From arylformamidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of arylformamidase alter kynurenine pathway flux? | AFMID knockout cell lines and mouse models |
| What is the effect of catalytic serine mutation on enzyme activity? | Point mutation (S-to-A) knock-in via CRISPR |
| Can tagged arylformamidase be used for localization studies? | Knock-in of fluorescent or epitope tag |
| Does overexpression of AFMID change metabolite levels? | Overexpression cell lines |
| Which genes interact with AFMID in cancer? | CRISPR library screening |
| How does organophosphate inhibition affect pathway? | Enzyme assays with recombinant mutant enzymes |
How to Study the arylformamidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | Conversion of N-formyl-L-kynurenine to L-kynurenine | Kinetic characterization of wild-type and mutant enzymes |
| X-ray crystallography | Three-dimensional structure of enzyme | Catalytic triad identification |
| LC-MS/MS metabolomics | Kynurenine pathway metabolite levels | Flux analysis in knockout cells |
| CRISPR knockout | Gene function loss | Phenotypic screening |
| Site-directed mutagenesis | Effect of point mutations | Catalytic residue validation |
| Western blot | Protein expression levels | Validation of knockout/overexpression |
| qRT-PCR | mRNA expression | Gene expression analysis |
| Immunofluorescence | Subcellular localization | Tagged knock-in studies |
Enzymatic Activity Assays
Arylformamidase activity is typically measured by monitoring the conversion of N-formyl-L-kynurenine to L-kynurenine using spectrophotometric or HPLC-based methods. Recombinant enzyme expressed in E. coli or mammalian cells can be used for kinetic studies.
Structural Biology
X-ray crystallography and homology modeling have elucidated the catalytic triad and substrate binding pocket of arylformamidase from Drosophila and rat. These methods guide mutagenesis and inhibitor design.
Metabolomics and Flux Analysis
LC-MS/MS-based metabolomics quantifies kynurenine pathway metabolites in cells or tissues, revealing changes in flux upon arylformamidase manipulation. Stable isotope tracing can further resolve pathway dynamics.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout screens can identify genes that modulate arylformamidase activity or kynurenine pathway output. Bioinformatics tools integrate expression data with pathway databases to predict regulatory networks.
How CRISPR Can Be Used to Study GO:0004061 arylformamidase activity
Knockout
CRISPR-Cas9 knockout of AFMID eliminates arylformamidase activity, enabling studies of kynurenine pathway flux and metabolite accumulation. Mouse models with Afmid gene inactivation have been generated and show altered enzymatic activity and phenotype. Knockout cell lines are valuable for cancer and neurobiology research.
Point Mutation
Point mutations in the catalytic triad (e.g., serine to alanine) can be introduced via CRISPR to dissect the enzymatic mechanism without affecting protein stability. Such models help distinguish catalytic activity from structural roles.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous AFMID locus allows real-time tracking of enzyme localization and interaction partners. This approach preserves native regulation and expression levels.
Overexpression
CRISPR activation or lentiviral overexpression of AFMID increases enzyme levels, useful for studying pathway saturation and gain-of-function phenotypes. Overexpression models can reveal dose-dependent effects on kynurenine metabolites.
How EDITGENE Supports arylformamidase activity Research
Researchers studying arylformamidase activity-related genes often need to determine whether a candidate gene is causally involved in kynurenine pathway regulation, disease progression, or drug response. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for arylformamidase activity research.
Frequently Asked Questions About arylformamidase activity
What is arylformamidase activity?
Arylformamidase activity (GO:0004061) is the catalysis of the reaction N-formyl-L-kynurenine + H2O = formate + L-kynurenine, a step in the kynurenine pathway.
What genes are involved in arylformamidase activity?
The primary gene is AFMID, encoding arylformamidase. Other kynurenine pathway genes include TDO2, IDO1, IDO2, KMO, KYNU, and QPRT.
What is the catalytic mechanism of arylformamidase?
It is a serine hydrolase with a catalytic triad (Ser-His-Asp/Glu) that hydrolyzes the formyl group from N-formyl-L-kynurenine.
Is arylformamidase inhibited by organophosphates?
Yes, organophosphorus toxicants inhibit serine hydrolases including arylformamidase by modifying the catalytic serine.
What diseases are linked to arylformamidase?
Dysregulation is implicated in cancer (e.g., bladder cancer) and neurological disorders due to altered kynurenine pathway metabolites.
How can I study arylformamidase activity in the lab?
Common methods include enzymatic assays, LC-MS/MS metabolomics, CRISPR knockout, and structural biology.
What animal models exist for arylformamidase?
Afmid knockout mice have been generated and show altered enzymatic activity and phenotype.
What is the GO ID for arylformamidase activity?
The Gene Ontology ID is GO:0004061.
What are synonyms for arylformamidase activity?
Synonyms include kynurenine formamidase activity, formylkynureninase activity, formamidase I, formamidase II, and formylase activity.
How does arylformamidase relate to the kynurenine pathway?
It catalyzes the conversion of N-formyl-L-kynurenine to L-kynurenine, a central step in the pathway.
Conclusion
Arylformamidase activity (GO:0004061) is a conserved serine hydrolase function that controls a key step in the kynurenine pathway. Its product, L-kynurenine, feeds into branches that produce neuroactive and immunomodulatory metabolites, linking the enzyme to cancer, neurological disorders, and toxicology. Structural and biochemical studies have defined its catalytic triad and mechanism, while mouse knockout models reveal physiological consequences. CRISPR-based models offer powerful tools to dissect its role in health and disease. EDITGENE provides comprehensive services to generate knockout, point mutation, knock-in, and overexpression models, as well as library screening and bioinformatics support, to advance research on arylformamidase activity.
References
- 1. Dobrovolsky VN et al.. 2005. Effect of arylformamidase (kynurenine formamidase) gene inactivation in mice on enzymatic activity, kynurenine pathway metabolites and phenotype.. Biochim Biophys Acta 1724(1-2):163-72 PMID: 15866519
- 2. Pabarcus MK et al.. 2005. Cloning, expression, and catalytic triad of recombinant arylformamidase.. Protein Expr Purif 44(1):39-44 PMID: 15935693
- 3. Casida JE et al.. 2005. Serine hydrolase targets of organophosphorus toxicants.. Chem Biol Interact 157-158:277-83 PMID: 16243304
- 4. Lemes DE et al.. 2026. Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression.. Int J Urol 33(5):e70491 PMID: 42095396
- 5. Tsuda H et al.. 1974. Formamidase in rat brain.. J Neurochem 22(5):679-83 PMID: 4135014
- 6. Han Q et al.. 2012. Biochemical identification and crystal structure of kynurenine formamidase from Drosophila melanogaster.. Biochem J 446(2):253-60 PMID: 22690733
- 7. Sommer T et al.. 2018. A fundamental catalytic difference between zinc and manganese dependent enzymes revealed in a bacterial isatin hydrolase.. Sci Rep 8(1):13104 PMID: 30166577
- 8. Pabarcus MK et al.. 2002. Kynurenine formamidase: determination of primary structure and modeling-based prediction of tertiary structure and catalytic triad.. Biochim Biophys Acta 1596(2):201-11 PMID: 12007602
